Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and BEAM Conditioning for Refractory Non-Hodgkin Lymphoma
NCT03583424Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in non-Hodgkin lymphoma (NHL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoints: Maximum Tolerated Dose of Venetoclax at 2 years and Overall Response Rate at 100 days. Started Sep 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03583424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583424.